Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 8:10:37-42.
doi: 10.2147/PROM.S163601. eCollection 2019.

Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes

Joanna C Robson  1   2 , David Jayne  3 , Peter A Merkel  4   5 , Jill Dawson  6
Affiliations
Review

Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes

Joanna C Robson et al. Patient Relat Outcome Meas. .

Abstract

The systemic vasculitides are a group of multisystem diseases, which can be life and organ threatening. High-dose immunosuppressants are required to control inflammation in vital organs, such as the kidneys, lungs, skin, joints, and eyes. Patients report a range of impacts on their health-related quality of life due to symptoms, irreversible damage, and the adverse effects of medications. The measurement of patient perspectives within clinical studies in vasculitis is essential to capture outcomes of greatest importance to patients. Validated generic, disease-specific and symptom-specific patient-reported outcomes available for use in patients with systemic vasculitis are reviewed here.

Keywords: ANCA-associated vasculitis; Behcet’s syndrome; clinical trials; large-vessel vasculitis; patient-related outcomes; vasculitis.

PubMed Disclaimer

Conflict of interest statement

Disclosure JCR, PAM, and JD developed the AAV-PRO. The authors report no other conflicts of interests in this work.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Luqmani R, Suppiah R, Edwards CJ, et al. Mortality in Wegener’s granulomatosis: a bimodal pattern. Rheumatology (Oxford) 2011;50(4):697–702. - PubMed
    1. Robson J, Doll H, Suppiah R, et al. Damage in the ANCA-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177–184. - PubMed
    1. Nazareth R, Mason JC. Takayasu arteritis: severe consequences of delayed diagnosis. QJM. 2011;104(9):797–800. - PubMed
    1. Jones RB, Tervaert JW, Hauser T, et al. European Vasculitis Study Group Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–220. - PubMed
    1. Stone JH, Tuckwell K, Dimonaco S, et al. Trial of Tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. - PubMed

LinkOut - more resources